Sight Sciences, Inc.
SGHTSight Sciences, Inc. in brief
Sight Sciences, Inc. is a listed company in the Medical Devices industry, based in Menlo Park, California, USA. It was founded in 2010. Its market value was $448 M on 1 August 2026, which makes it the 13,062nd largest listed company in the world and the 2,602nd largest in the USA on this site. In the year to December 2025 it had sales of $77 M and a net loss of $38 M. It employs about 186 people and Paul Badawi is its chief executive. Its largest business segments by sales in 2025 were Interventional Glaucoma (98%) and Interventional Dry Eye (2%). Its shares trade under the symbol SGHT (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Sight Sciences, Inc.
Our mission is to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing. We are passionate about improving patients’ lives by helping them to preserve their sight. Our business philosophy is grounded in the following principles: comprehensively understanding disease physiology; developing transformative technologies that are intended to preserve, protect, and restore natural physiological functionality to diseased eyes; developing and marketing products with proven clinical evidence that achieve superior effectiveness versus current treatment paradigms while minimizing complications or side effects; providing intuitive, patient-friendly, interventional solutions to eye care professionals; and delivering compelling economic value to all stakeholders, including patients, providers and third-party payors such as Medicare and commercial insurers. Our objective is to develop and market products for use in new treatment paradigms and to create an interventional mindset in eyecare whereby our technologies may be used in procedures which supplant conventional outdated approaches.
From the company's annual report filed with the US SEC: read the report
Sight Sciences, Inc. timeline
- 2010
- 🏁· approximateFounded
- 2011
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 15 July 2021; shares registered for exchange trading on 8 July 2021.
- 2023
- 💰Record revenue of $81 millionFY2023, the highest of the 6 years on record.
Events of Sight Sciences, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,819 (Jan 2022) · #2,463 (Dec 2022) · #2,839 (Jul 2023) · #3,091 (Jan 2024) · #1,704 (Mar 2026) · #2,600 (Aug 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 5.1×
- Price / book
- 7.0×
- Free cash flow yield
- -6.7%
- Net margin (TTM)
- -32.1%
- Operating margin
- -48.0%
- Return on equity
- -44.4%
- Liabilities / assets
- 44.5%
- Net debt
- $-50M
- Revenue growth
- -3.1%
- R&D / revenue
- 18.9%
- Revenue per employee
- $416 K
- Profit per employee
- $-207 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $77M | -3.1% | $-37M | $-38M | -49.7% |
| Dec 2024 | $80M | -1.5% | $-51M | $-52M | -64.5% |
| Dec 2023 | $81M | +13.6% | $-57M | $-56M | -68.5% |
| Dec 2022 | $71M | +45.7% | $-84M | $-86M | -120.9% |
| Dec 2021 | $49M | +77.1% | $-51M | $-63M | -128.6% |
| Dec 2020 | $28M | — | $-32M | $-35M | -125.5% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-30M | $0M | $-30M | $-0.74 | — |
| Dec 2024 | $-22M | $0M | $-23M | $-1.03 | — |
| Dec 2023 | $-47M | $1M | $-48M | $-1.14 | — |
| Dec 2022 | $-76M | $1M | $-77M | $-1.80 | — |
| Dec 2021 | $-53M | $1M | $-53M | $-2.36 | — |
| Dec 2020 | $-32M | $1M | $-33M | $-3.71 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $25M (+25.2% on a year earlier), net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 4, 202610-QQuarterly report · period to Sep 2026
- Nov 4, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Aug 10, 20268-KCurrent reportDirectors or officers changed
- Aug 5, 202610-QQuarterly report · period to Jun 2026
- Aug 5, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Jun 5, 20268-KCurrent reportShareholder vote
- May 6, 202610-QQuarterly report · period to Mar 2026
- May 6, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Apr 23, 20268-KCurrent reportRegulation FD disclosure
- Apr 22, 2026DEF 14AProxy statement
- Mar 30, 20268-KCurrent reportRegulation FD disclosure
- Mar 4, 202610-KAnnual report · period to Dec 2025
Official filings of Sight Sciences, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $77 M
- Operating income
- $-37 M
- Net income
- $-38 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $115 M
- Total liabilities
- $51 M
- Total equity
- $64 M
As of December-2025
Top 100 institutional investors in Sight Sciences, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Long Focus Capital Management, LLC | 3,844,100 | 0 (0.00%) | 6.92% | $36 M | Nov 16, 2026 |
| 2 | BlackRock, Inc. | 3,361,212 | +278,104 (+9.02%) | 6.05% | $31 M | Nov 13, 2026 |
| 3 | Pathstone Holdings, LLC | 2,186,524 | +507,544 (+30.23%) | 3.93% | $20 M | Nov 13, 2026 |
| 4 | Vanguard Capital Management LLC | 1,635,379 | +61,564 (+3.91%) | 2.94% | $15 M | Nov 13, 2026 |
| 5 | Geode Capital Management, LLC | 979,093 | +20,528 (+2.14%) | 1.76% | $9 M | Nov 6, 2026 |
| 6 | B Group, Inc. | 970,000 | 0 (0.00%) | 1.75% | $9 M | Nov 16, 2026 |
| 7 | Acadian Asset Management LLC | 844,119 | +37,543 (+4.65%) | 1.52% | $8 M | Nov 9, 2026 |
| 8 | State Street Corp | 840,635 | +5,183 (+0.62%) | 1.51% | $8 M | Nov 12, 2026 |
| 9 | Millennium Management LLC | 709,451 | +634,144 (+842.08%) | 1.28% | $7 M | Nov 16, 2026 |
| 10 | Dimensional Fund Advisors LP | 370,755 | -12,757 (-3.33%) | 0.67% | $3 M | Nov 4, 2026 |
| 11 | Northern Trust Corp | 354,044 | +10,462 (+3.04%) | 0.64% | $3 M | Nov 16, 2026 |
| 12 | D. E. Shaw & Co., Inc. | 349,051 | +69,102 (+24.68%) | 0.63% | $3 M | Nov 16, 2026 |
| 13 | Charles Schwab Investment Management Inc | 324,254 | +48,701 (+17.67%) | 0.58% | $3 M | Nov 16, 2026 |
| 14 | Panagora Asset Management Inc | 298,693 | +36,165 (+13.78%) | 0.54% | $3 M | Nov 12, 2026 |
| 15 | Next Century Growth Investors LLC | 289,863 | New | 0.52% | $3 M | Nov 13, 2026 |
| 16 | Jacobs Levy Equity Management, Inc | 283,230 | -55,211 (-16.31%) | 0.51% | $3 M | Nov 16, 2026 |
| 17 | Vanguard Fiduciary Trust Co | 281,576 | +25,498 (+9.96%) | 0.51% | $3 M | Nov 13, 2026 |
| 18 | AQR Capital Management LLC | 278,501 | -119,057 (-29.95%) | 0.50% | $3 M | Nov 16, 2026 |
| 19 | Goldman Sachs Group Inc | 278,044 | +77,917 (+38.93%) | 0.50% | $3 M | Nov 16, 2026 |
| 20 | Vanguard Portfolio Management LLC | 276,435 | +3,950 (+1.45%) | 0.50% | $3 M | Nov 13, 2026 |
| 21 | Morgan Stanley | 215,601 | +60,379 (+38.90%) | 0.39% | $2 M | Nov 13, 2026 |
| 22 | Invesco Ltd. | 214,173 | +192,899 (+906.74%) | 0.39% | $2 M | Nov 12, 2026 |
| 23 | Qube Research & Technologies Ltd | 199,219 | -163,484 (-45.07%) | 0.36% | $2 M | Nov 13, 2026 |
| 24 | Renaissance Technologies LLC | 195,858 | -16,800 (-7.90%) | 0.35% | $2 M | Nov 12, 2026 |
| 25 | Lazard Asset Management LLC | 190,731 | +66,176 (+53.13%) | 0.34% | $2 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Royce & Associates LP | 179,043 | New | 0.32% | $2 M | Nov 9, 2026 |
| 27 | Gsa Capital Partners LLP | 156,486 | -11,078 (-6.61%) | 0.28% | $1 M | Nov 16, 2026 |
| 28 | Topline Capital Management, LLC | 144,372 | New | 0.26% | $1 M | Nov 16, 2026 |
| 29 | Nuveen, LLC | 144,069 | +49,492 (+52.33%) | 0.26% | $1 M | Nov 10, 2026 |
| 30 | Bank Of America Corp /de/ | 140,076 | +44,043 (+45.86%) | 0.25% | $1 M | Nov 16, 2026 |
| 31 | Palumbo Wealth Management LLC | 133,394 | +4,858 (+3.78%) | 0.24% | $1 M | Nov 13, 2026 |
| 32 | Citadel Advisors LLC | 126,564 | -89,743 (-41.49%) | 0.23% | $1 M | Nov 16, 2026 |
| 33 | Informed Momentum Co LLC | 108,956 | New | 0.20% | $1 M | Nov 16, 2026 |
| 34 | Squarepoint Ops LLC | 102,560 | -115,548 (-52.98%) | 0.18% | $1 M | Nov 9, 2026 |
| 35 | Two Sigma Investments, LP | 97,683 | +56,739 (+138.58%) | 0.18% | $1 M | Nov 16, 2026 |
| 36 | UBS Group AG | 96,375 | -29,719 (-23.57%) | 0.17% | $1 M | Nov 10, 2026 |
| 37 | Bank of New York Mellon Corp | 94,432 | +3,041 (+3.33%) | 0.17% | $1 M | Nov 5, 2026 |
| 38 | XTX Topco Ltd | 94,041 | -1,726 (-1.80%) | 0.17% | $1 M | Nov 16, 2026 |
| 39 | SCS Capital Management LLC | 90,000 | 0 (0.00%) | 0.16% | $1 M | Nov 12, 2026 |
| 40 | SEI Investments Co | 88,015 | New | 0.16% | $1 M | Nov 10, 2026 |
| 41 | Balyasny Asset Management L.P. | 80,168 | New | 0.14% | $1 M | Nov 16, 2026 |
| 42 | Bridgeway Capital Management, LLC | 76,187 | +10,454 (+15.90%) | 0.14% | $1 M | Nov 16, 2026 |
| 43 | Walleye Capital LLC | 71,073 | New | 0.13% | $1 M | Nov 13, 2026 |
| 44 | Integrated Quantitative Investments LLC | 67,838 | +32,682 (+92.96%) | 0.12% | $1 M | Nov 13, 2026 |
| 45 | State Of Wisconsin Investment Board | 66,837 | +25,637 (+62.23%) | 0.12% | $1 M | Nov 16, 2026 |
| 46 | Empowered Funds, LLC | 65,987 | New | 0.12% | $1 M | Nov 13, 2026 |
| 47 | Parallel Advisors, LLC | 59,239 | -5,156 (-8.01%) | 0.11% | $1 M | Nov 3, 2026 |
| 48 | Point72 Asset Management, L.P. | 54,994 | +38,869 (+241.05%) | 0.10% | $1 M | Nov 16, 2026 |
| 49 | Jpmorgan Chase & Co | 48,786 | +2,558 (+5.53%) | 0.09% | $0 M | Nov 12, 2026 |
| 50 | Prudential Financial Inc | 47,602 | New | 0.09% | $0 M | Nov 16, 2026 |
| 51 | Rhumbline Advisers | 46,844 | -1,705 (-3.51%) | 0.08% | $0 M | Nov 10, 2026 |
| 52 | HSBC Holdings PLC | 46,707 | 0 (0.00%) | 0.08% | $0 M | Nov 16, 2026 |
| 53 | Canada Pension Plan Investment Board | 46,600 | -8,500 (-15.43%) | 0.08% | $0 M | Nov 16, 2026 |
| 54 | Occudo Quantitative Strategies LP | 41,465 | +16,998 (+69.47%) | 0.07% | $0 M | Nov 16, 2026 |
| 55 | Hillsdale Investment Management Inc. | 39,300 | New | 0.07% | $0 M | Nov 12, 2026 |
| 56 | Alliancebernstein L.P. | 38,880 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 57 | Barclays PLC | 35,990 | +9,408 (+35.39%) | 0.06% | $0 M | Nov 6, 2026 |
| 58 | Foster Victor Wealth Advisors, LLC | 35,895 | 0 (0.00%) | 0.06% | $0 M | Oct 21, 2026 |
| 59 | Deutsche Bank AG\ | 33,776 | -201 (-0.59%) | 0.06% | $0 M | Nov 6, 2026 |
| 60 | Price T Rowe Associates Inc /MD/ | 32,294 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 61 | Public Employees Retirement System Of Ohio | 32,139 | New | 0.06% | $0 M | Nov 16, 2026 |
| 62 | Susquehanna International Group, LLP | 28,394 | New | 0.05% | $0 M | Nov 16, 2026 |
| 63 | Ieq Capital, LLC | 26,635 | +1,803 (+7.26%) | 0.05% | $0 M | Nov 10, 2026 |
| 64 | Algert Global LLC | 25,966 | -2,300 (-8.14%) | 0.05% | $0 M | Nov 17, 2026 |
| 65 | MetLife Investment Management, LLC | 23,019 | -751 (-3.16%) | 0.04% | $0 M | Nov 16, 2026 |
| 66 | Russell Investments Group, Ltd. | 22,563 | -187,598 (-89.26%) | 0.04% | $0 M | Nov 6, 2026 |
| 67 | R Squared Ltd | 19,759 | +3,388 (+20.70%) | 0.04% | $0 M | Nov 6, 2026 |
| 68 | Diversified Trust Co | 18,989 | +4,068 (+27.26%) | 0.03% | $0 M | Nov 6, 2026 |
| 69 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 18,804 | +683 (+3.77%) | 0.03% | $0 M | Nov 16, 2026 |
| 70 | Kemnay Advisory Services Inc. | 15,706 | +9,090 (+137.39%) | 0.03% | $0 M | Nov 16, 2026 |
| 71 | Graham Capital Management, L.P. | 14,846 | -19,778 (-57.12%) | 0.03% | $0 M | Nov 16, 2026 |
| 72 | Quadrature Capital Ltd | 14,794 | New | 0.03% | $0 M | Nov 13, 2026 |
| 73 | Wealth Enhancement Advisory Services, LLC | 13,918 | -50 (-0.36%) | 0.03% | $0 M | Oct 13, 2026 |
| 74 | Vanguard Global Advisers, LLC | 13,794 | +202 (+1.49%) | 0.02% | $0 M | Nov 13, 2026 |
| 75 | Police & Firemen's Retirement System of New Jersey | 12,603 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 76 | WealthTrust Asset Management, LLC | 12,500 | -8,456 (-40.35%) | 0.02% | $0 M | Oct 22, 2026 |
| 77 | Schonfeld Strategic Advisors LLC | 12,259 | New | 0.02% | $0 M | Nov 16, 2026 |
| 78 | Creative Planning | 12,130 | New | 0.02% | $0 M | Nov 2, 2026 |
| 79 | Wells Fargo & Company/mn | 11,960 | -23,941 (-66.69%) | 0.02% | $0 M | Nov 16, 2026 |
| 80 | Bank Of Montreal /can/ | 11,755 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 81 | Savant Capital, LLC | 11,709 | New | 0.02% | $0 M | Nov 6, 2026 |
| 82 | Mariner, LLC | 10,933 | New | 0.02% | $0 M | Nov 12, 2026 |
| 83 | Manufacturers Life Insurance Company, The | 10,867 | -226 (-2.04%) | 0.02% | $0 M | Nov 13, 2026 |
| 84 | Principal Financial Group Inc | 10,845 | New | 0.02% | $0 M | Nov 2, 2026 |
| 85 | Arrowstreet Capital, Limited Partnership | 10,788 | New | 0.02% | $0 M | Nov 13, 2026 |
| 86 | Vanguard Personalized Indexing Management, LLC | 10,193 | -282 (-2.69%) | 0.02% | $0 M | Nov 16, 2026 |
| 87 | Brevan Howard Capital Management LP | 10,190 | New | 0.02% | $0 M | Nov 16, 2026 |
| 88 | BNP Paribas Financial Markets | 10,078 | +3,639 (+56.51%) | 0.02% | $0 M | Nov 12, 2026 |
| 89 | New York State Common Retirement Fund | 8,685 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 90 | Signaturefd, LLC | 8,433 | 0 (0.00%) | 0.02% | $0 M | Oct 23, 2026 |
| 91 | FMR LLC | 8,144 | +264 (+3.35%) | 0.01% | $0 M | Nov 10, 2026 |
| 92 | Federated Hermes, Inc. | 6,560 | +4,744 (+261.23%) | 0.01% | $0 M | Nov 12, 2026 |
| 93 | Conquis Financial LLC | 5,000 | 0 (0.00%) | 0.01% | $0 M | Nov 10, 2026 |
| 94 | Legal & General Group Plc | 3,766 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 95 | Ameritas Investment Partners, Inc. | 3,442 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 96 | Royal Bank Of Canada | 3,023 | +124 (+4.28%) | 0.01% | $0 M | Nov 16, 2026 |
| 97 | Arax Advisory Partners | 2,872 | +133 (+4.86%) | 0.01% | $0 M | Nov 12, 2026 |
| 98 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2,406 | +1,918 (+393.03%) | 0.00% | $0 M | Nov 16, 2026 |
| 99 | Caldwell Sutter Capital, Inc. | 2,000 | 0 (0.00%) | 0.00% | $0 M | Nov 9, 2026 |
| 100 | Citigroup Inc | 1,951 | -16,483 (-89.42%) | 0.00% | $0 M | Nov 4, 2026 |
Mutual funds holding Sight Sciences, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.14 M | $6 M | 1.3% | <0.01% | +8.4% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.03 M | $6 M | 1.2% | <0.01% | +0.9% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 429,723 | $2 M | 0.50% | <0.01% | +3.7% | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 381,573 | $2 M | 0.45% | <0.01% | +5.0% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 374,550 | $2 M | 0.44% | 0.01% | +9.2% | Jun 30, 2026 |
| 🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors | 269,592 | $1 M | 0.32% | 0.03% | +29% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 215,532 | $1 M | 0.25% | <0.01% | +4.4% | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 177,218 | $1 M | 0.21% | <0.01% | +5.6% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 163,525 | $1 M | 0.19% | <0.01% | −1.6% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 132,333 | $1 M | 0.16% | 0.05% | +26% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 101,539 | $1 M | 0.12% | <0.01% | +0.7% | Jul 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 92,208 | $0 M | 0.11% | <0.01% | +0.2% | Jul 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 83,670 | $0 M | 0.10% | <0.01% | +5.4% | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 71,563 | $0 M | 0.08% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 57,660 | $0 M | 0.07% | <0.01% | +333% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 64,020 | $0 M | 0.08% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 55,533 | $0 M | 0.07% | 0.20% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 47,645 | $0 M | 0.06% | <0.01% | −1.2% | Jun 30, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 47,057 | $0 M | 0.06% | <0.01% | +8.8% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 47,520 | $0 M | 0.06% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 51,303 | $0 M | 0.06% | <0.01% | +4.5% | May 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 43,335 | $0 M | 0.05% | <0.01% | +19% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 36,679 | $0 M | 0.04% | 0.01% | +15% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 39,124 | $0 M | 0.05% | 0.01% | +3.1% | May 31, 2026 |
| 🇺🇸 Clearwater Select Equity FundClearwater Management Co Inc. | 31,829 | $0 M | 0.04% | 0.03% | +101% | Jun 30, 2026 |
| 🇺🇸 SIMT Tax-Managed Small/Mid Cap FundSEI Institutional Managed Trust | 30,000 | $0 M | 0.04% | 0.02% | −38% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 33,203 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 27,900 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 22,390 | $0 M | 0.03% | <0.01% | +7.2% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 19,964 | $0 M | 0.02% | <0.01% | −12% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 18,531 | $0 M | 0.02% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 18,779 | $0 M | 0.02% | <0.01% | +2.1% | Jul 31, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 20,000 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 17,749 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 17,683 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC | 18,093 | $0 M | 0.02% | 0.04% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 17,823 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 16,674 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 14,900 | $0 M | 0.02% | <0.01% | +9.6% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 14,862 | $0 M | 0.02% | <0.01% | +11% | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 13,916 | $0 M | 0.02% | <0.01% | +60% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 12,918 | $0 M | 0.02% | <0.01% | +8.8% | Jul 31, 2026 |
| 🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc. | 11,435 | $0 M | 0.01% | <0.01% | −6.7% | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 11,168 | $0 M | 0.01% | 0.02% | −4.5% | Jun 30, 2026 |
| 🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC | 10,907 | $0 M | 0.01% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 10,600 | $0 M | 0.01% | <0.01% | +16% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 10,444 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 8,919 | $0 M | 0.01% | 0.02% | +15% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 9,004 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 8,346 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 8,072 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 8,068 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 7,943 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 7,402 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 6,330 | $0 M | <0.01% | <0.01% | +18% | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 6,056 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 5,993 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 5,934 | $0 M | <0.01% | <0.01% | +31% | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 5,711 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 5,287 | $0 M | <0.01% | <0.01% | +2.9% | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 4,696 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc. | 4,080 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 4,161 | $0 M | <0.01% | <0.01% | +25% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 4,114 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 3,442 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 3,421 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 3,395 | $0 M | <0.01% | <0.01% | +8.1% | Jul 31, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 3,387 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 3,139 | $0 M | <0.01% | <0.01% | +8.1% | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 3,207 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 3,054 | $0 M | <0.01% | 0.01% | +0.5% | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Core Equity FundJackson National Asset Management, LLC | 2,679 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 2,673 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation | 2,552 | $0 M | <0.01% | <0.01% | −5.3% | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 2,472 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 LVIP Dimensional U.S. Core Equity 2 FundLincoln Financial Investments Corporation | 2,357 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC | 2,351 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 2,400 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 1,839 | $0 M | <0.01% | <0.01% | −48% | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 1,970 | $0 M | <0.01% | <0.01% | +8.7% | May 31, 2026 |
| 🇺🇸 Vy Jpmorgan Small Cap Core Equity PortfolioVoya Investments, LLC | 1,680 | $0 M | <0.01% | <0.01% | −5.0% | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,454 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 1,557 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 1,548 | $0 M | <0.01% | <0.01% | −5.1% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 1,540 | $0 M | <0.01% | <0.01% | −41% | May 31, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 1,119 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 1,044 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 900 | $0 M | <0.01% | <0.01% | −18% | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 845 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 781 | $0 M | <0.01% | <0.01% | −35% | Jun 30, 2026 |
| 🇺🇸 SA Multi-Managed Small Cap PortfolioSunAmerica Asset Management, LLC | 539 | $0 M | <0.01% | <0.01% | −9.1% | Jun 30, 2026 |
| 🇺🇸 Avantis Total Equity Markets ETFAmerican Century ETF Trust | 384 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 204 | $0 M | <0.01% | <0.01% | +8.5% | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 10 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 94 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Sight Sciences, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Brenton TaylorEVP, Operations & R&D | Sell10b5-1 plan | -20,685 | $10.64 | $220 K | 241,305 | Form 4 |
| filed | James RodbergChief Financial Officer | Sell10b5-1 plan | -7,208 | $8.853 | $64 K | 216,829 | Form 4 |
| filed | Alison BauerleinChief Operating Officer | Sell10b5-1 plan | -25,260 | $8.853 | $224 K | 639,449 | Form 4 |
| filed | Brenton TaylorEVP, Operations & R&D | Sell10b5-1 plan | -2,988 | $8.853 | $26 K | 261,990 | Form 4 |
| filed | Paul BadawiPresident and CEO, Director, 10% owner | Sell10b5-1 plan | -29,653 | $9.049 | $268 K | 6.09 M | Form 4 |
| filed | David BadawiChief Technology Officer, Director | Sell10b5-1 plan | -7,797 | $9.049 | $71 K | 1.98 M | Form 4 |
| filed | Kashif RashidChief Legal Officer | Grant or award | +181,818 | — | — | 181,818 | Form 4 |
| filed | David BadawiChief Technology Officer, Director | Sell10b5-1 plan | -7,418 | $5.510 | $41 K | 1.98 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Sight Sciences, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 9 shares at $8.38
- : 5,220 shares at $5.64
- : 2,210 shares at $5.53
- : 539 shares at $5.05
- : 13 shares at $5.46
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Sight Sciences, Inc. scorecard#
Passes 4 of the 18 checks that could be worked out: strongest in financial health (3 of 6), weakest in growth (0 of 6). Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth0 of 6
- ✗Revenue grew in the newest year-3.1%Revenue down 3.1% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years2.7%2.7% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median2.7%2.7% a year against Medical Devices's median of 10.8% (73 companies).
- ✗Earnings per share grew in the newest year-0.74 vs -1.03Diluted EPS -0.74 in fiscal 2025 against -1.03 the year before (report's currency).
- ✗Net income higher than five years earlier-$38 M-$38 M in fiscal 2025 against -$35 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$38 MNet income -$38 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-48.0%-48.0% against Medical Devices's median of -8.2% (86 companies).
- ✗Return on equity above 15%-50.8%-50.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-48.0%-48.0% in fiscal 2025 against -117.7% in 2022.
Financial health3 of 6
- ✓Short-term assets cover short-term liabilities10.2×Current ratio 10.22 at the end of fiscal 2025.
- ✓Debt below equity0.7×Debt to equity 0.66 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $50 M at the end of fiscal 2025.
- ✗Operating income covers interest five times-7.2×Operating income -7.2 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone1.23Z-score 1.23 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year4.0%Diluted shares up 4.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Sight Sciences, Inc.'s statements, beside the median of Medical Devices.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -48.0% | -8.2% | |
| Net margin | -49.7% | -10.4% | |
| Return on equity | -50.8% | -16.8% | |
| Revenue growth, 3 years a year | 2.7% | 10.8% | |
| Revenue growth | -3.1% | 10.4% | |
| Debt to equity | 0.66× | 0.64× |
5of 9on the Piotroski tests of financial strength
- Revenue fell 3.1% against the year before.
- Net loss of $38 million, the 6th loss-making year in a row.
- Free cash flow was negative: -$30 million.
- Operating income covers the interest bill only -7.2 times.
Sight Sciences, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 77−3.1%100% | 80−1.5%100% | 81+13.6%100% | 71+45.7%100% | 49+77.1%100% | 28—100% | |
| Cost of revenue | 11−7.6%13.8% | 12−2.5%14.5% | 12−3.9%14.7% | 12+43.6%17.3% | 8.6−6.5%17.6% | 9.2—33.3% | |
| Gross profit | 67−2.4%86.2% | 68−1.3%85.5% | 69+17.3%85.3% | 59+46.2%82.7% | 40+119%82.4% | 18—66.7% | |
| Research and development | 15−18.8%18.9% | 18+2.5%22.5% | 18−23.2%21.7% | 23+46.2%32.0% | 16+76.2%31.9% | 8.9—32.1% | |
| Selling, general and administrative | 89−11.6%115% | 101−7.4%126% | 109−9.3%134% | 120+57.6%168% | 76+82.5%156% | 42—151% | |
| General and administrative | — | — | — | — | — | 1.8—6.5% | |
| Operating expenses | 104−12.7%134% | 119−6.0%149% | 126−11.5%156% | 143+55.6%200% | 92+81.4%188% | 51—183% | |
| Operating income | −37—−48.0% | −51—−63.3% | −57—−70.7% | −84—−118% | −51—−105% | −32—−116% | |
| Interest and finance income | — | — | — | — | — | 0.0—0.1% | |
| Interest expense and finance costs | 5.1+10.3%6.6% | 4.7−13.8%5.8% | 5.4+21.1%6.7% | 4.5+2.3%6.3% | 4.4+81.7%8.9% | 2.4—8.7% | |
| Other non-operating income (expense) | −0.1—−0.2% | −0.0—−0.0% | −0.0r7.2−102%−0.1% | 2.2—3.1% | −6.9—−14.2% | −0.1—−0.3% | |
| Income before tax | −38—−49.7% | −51—−64.2% | −55—−68.4% | −86—−121% | −63—−128% | −35—−125% | |
| Income tax | 0.0−95.8%0.0% | 0.2+115%0.3% | 0.1+134%0.1% | 0.0−75.0%0.1% | 0.2+208%0.4% | 0.1—0.2% | |
| Net income including minority interests | −38—−49.7% | −52—−64.5% | −56—−68.5% | −86—−121% | −63—−129% | −35—−126% | |
| Net income attributable to shareholders | −38—−49.7% | −52—−64.5% | −56—−68.5% | −86—−121% | −63—−129% | −35—−126% | |
| Earnings per share, basic | -0.74—— | -1.03—— | -1.14—— | -1.80—— | -2.36—— | -3.71—— | |
| Earnings per share, diluted | -0.74—— | -1.03—— | -1.14—— | -1.80—— | -2.36—— | -3.71—— | |
| Shares, weighted average (basic) | 52+4.0%— | 50+3.1%— | 49+1.6%— | 48+79.0%— | 27—— | — | |
| Shares, weighted average (diluted) | 52+4.0%— | 50+3.1%— | 49+1.6%— | 48+79.0%— | 27+186%— | 9.4—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 92−23.6%79.8% | 120−12.9%84.3% | 138−25.3%82.9% | 185−29.0%86.8% | 261+324%93.0% | 62—84.5% | |
| Receivables | 9.7−9.7%8.5% | 11−24.5%7.6% | 14−5.7%8.6% | 15+73.9%7.1% | 8.7+62.4%3.1% | 5.4—7.4% | |
| Inventory | 7.8+22.8%6.7% | 6.3−19.4%4.4% | 7.8+28.4%4.7% | 6.1+75.9%2.9% | 3.5+33.8%1.2% | 2.6—3.6% | |
| Other current assets | 3.3+41.2%2.8% | 2.3−11.4%1.6% | 2.6−23.7%1.6% | 3.4−18.0%1.6% | 4.2+259%1.5% | 1.2—1.6% | |
| Current assets | 113−19.3%97.8% | 140−14.2%97.9% | 163−22.3%97.7% | 210−24.3%98.4% | 277+292%98.9% | 71—97.0% | |
| Property, plant and equipment | 1.6+1.9%1.4% | 1.6−3.7%1.1% | 1.6+4.4%1.0% | 1.6+8.0%0.7% | 1.5+14.6%0.5% | 1.3—1.7% | |
| Right-of-use (leased) assets | 0.4−53.2%0.4% | 0.9−35.9%0.7% | 1.5−9.7%0.9% | 1.6+8.0%0.8% | 1.5+189%0.5% | 0.5—0.7% | |
| Total assets | 115−19.3%100% | 143−14.3%100% | 167−21.8%100% | 213−24.0%100% | 280+285%100% | 73—100% | |
| Accounts payable | 1.3−20.6%1.2% | 1.7−2.3%1.2% | 1.7−35.6%1.0% | 2.7−19.8%1.3% | 3.4+55.3%1.2% | 2.2—3.0% | |
| Debt due within a year | 0—0.0% | 0−100%0.0% | 2.2—1.3% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Current liabilities | 11−28.7%9.6% | 15+26.2%10.8% | 12−31.2%7.4% | 18+31.9%8.4% | 14+45.0%4.8% | 9.3—12.8% | |
| Long-term debt | 40+2.4%35.0% | 39+24.1%27.6% | 32−4.8%19.0% | 33+2.0%15.6% | 33+2.2%11.7% | 32—43.9% | |
| Lease liabilities (non-current) | 0−100%0.0% | 0.5−48.2%0.3% | 0.9+43.9%0.5% | 0.6−38.9%0.3% | 1.0+676%0.4% | 0.1—0.2% | |
| Total liabilities | 51−7.2%44.5% | 55+19.1%38.7% | 46−12.4%27.9% | 53+10.2%24.9% | 48+8.5%17.2% | 44—60.9% | |
| Retained earnings | −385—−334% | −346—−242% | −295—−177% | −239—−112% | −153—−54.6% | −90—−124% | |
| Shareholders' equity | 64−26.9%55.5% | 88−27.2%61.3% | 120−24.9%72.1% | 160−31.0%75.1% | 232—82.8% | −89—−122% | |
| Total liabilities and equity | 115−19.3%100% | 143−14.3%100% | 167−21.8%100% | 213−24.0%100% | 280+285%100% | 73—100% | |
| Shares outstanding | 53+5.0%— | 51+3.7%— | 49+1.7%— | 48+1.7%— | 48+400%— | 9.5—— | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 0.5−31.6%0.6% | 0.7+16.0%0.9% | 0.6—0.8% | — | — | — | |
| Share-based compensation | 13−23.6%16.9% | 17+17.1%21.4% | 15+12.5%18.0% | 13+155%18.2% | 5.1+923%10.4% | 0.5—1.8% | |
| Cash from operating activities | −30—−38.4% | −22—−28.0% | −47—−58.2% | −76—−106% | −53—−107% | −32—−116% | |
| Capital expenditure | −0.2—−0.3% | −0.4—−0.5% | −0.8—−1.0% | −1.0—−1.4% | −0.8—−1.7% | −1.0—−3.4% | |
| Cash from investing activities | −0.2—−0.3% | −0.4—−0.5% | −0.8—−1.0% | −1.0—−1.4% | −0.8—−1.7% | −1.0—−3.4% | |
| Debt issued | — | — | — | — | 0−100%0.0% | 20—74.1% | |
| Cash from financing activities | 1.8−63.9%2.3% | 5.0+350%6.2% | 1.1−11.5%1.4% | 1.2−99.5%1.7% | 253+244%516% | 73—266% | |
| Change in cash | −28—−36.4% | −18—−22.3% | −47—−57.8% | −76−138%−106% | 199+395%407% | 40—146% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 88+16.2%100% | 25+25.2%100% | 23+19.5%100% | 20+12.5%100% | 20*+6.9%100% | 20−1.2%100% | 20−8.5%100% | 18−9.1%100% | 19*+1.7%100% | 20—100% | 21—100% | 19—100% | 19*—100% | |
| Cost of revenue | 11+2.1%12.3% | 3.5+29.3%14.1% | 2.0−32.3%8.6% | 2.7+12.7%13.8% | 2.6*+3.3%12.7% | 2.7−16.6%13.6% | 3.0−1.6%15.2% | 2.4−13.6%13.8% | 2.5*−9.5%13.2% | 3.3—16.1% | 3.0—14.2% | 2.8—14.5% | 2.8*—14.8% | |
| Gross profit | 78+18.5%87.7% | 21+24.6%85.9% | 21+28.9%91.4% | 17+12.5%86.2% | 18*+7.4%87.3% | 17+1.7%86.4% | 17−9.6%84.8% | 15−8.4%86.2% | 17*+3.7%86.8% | 17—83.9% | 18—85.8% | 16—85.5% | 16*—85.2% | |
| Research and development | 10−38.0%11.5% | 2.7−19.3%10.9% | 2.5−42.7%10.7% | 2.5−42.5%12.9% | 2.4*−43.2%12.0% | 3.4−29.4%16.8% | 4.4+1.6%22.4% | 4.4−4.4%25.3% | 4.3*+25.3%22.5% | 4.7—23.5% | 4.3—20.2% | 4.6—24.1% | 3.4*—18.3% | |
| Selling, general and administrative | 93−0.9%106% | 25+14.2%99.7% | 23−4.7%97.3% | 27+9.5%136% | 19*−21.4%93.3% | 22−7.0%109% | 24−10.5%122% | 25−7.7%140% | 24*+2.3%127% | 23—116% | 27—125% | 27—138% | 24*—126% | |
| Operating expenses | 104−6.4%117% | 28+9.7%111% | 25−10.6%108% | 29+1.5%149% | 21*−24.7%105% | 25−10.8%126% | 28−8.8%144% | 29−7.2%165% | 28*+5.2%149% | 28—140% | 31—145% | 31—162% | 27*—144% | |
| Operating income | −26—−29.5% | −6.1—−24.6% | −3.9—−16.6% | −12—−63.0% | −3.7*—−18.0% | −7.9—−39.7% | −12—−59.6% | −14—−79.2% | −12*—−62.5% | −11—−55.7% | −13—−59.2% | −15—−76.4% | −11*—−59.3% | |
| Interest expense and finance costs | 5.2+2.9%5.8% | 1.3+0.5%5.3% | 1.3+0.5%5.5% | 1.3+0.4%6.4% | 1.3*+11.0%6.3% | 1.3+13.5%6.6% | 1.3+12.1%6.6% | 1.3+4.9%7.2% | 1.2*−14.1%6.1% | 1.2—5.7% | 1.1—5.4% | 1.2—6.2% | 1.4*—7.2% | |
| Other non-operating income (expense) | −0.0—−0.0% | −0.1—−0.2% | 0.1+242%0.4% | −0.0—−0.1% | −0.0*—−0.1% | −0.0−108%−0.0% | 0.0—0.1% | −0.1—−0.8% | −0.0*—−0.0% | 0.0—0.1% | −0.0—−0.2% | −0.0—−0.0% | −0.0r1.8*—−0.1% | |
| Income before tax | −28—−32.1% | −6.8—−27.3% | −4.4—−18.9% | −13—−65.8% | −4.2*—−20.4% | −8.2—−41.4% | −12—−60.8% | −14—−80.6% | −12*—−61.9% | −11—−54.1% | −12—−57.6% | −16—−84.3% | −11*—−57.0% | |
| Income tax | 0.1+45.0%0.1% | 0.0—0.0% | 0.0−30.0%0.1% | 0.0−73.2%0.1% | 0.0*−78.9%0.0% | −0.1−148%−0.4% | 0.0+167%0.2% | 0.0+141%0.2% | 0.0*+280%0.2% | 0.2—0.8% | 0.0—0.1% | 0.0—0.1% | 0.0*—0.1% | |
| Net income including minority interests | −28—−32.1% | −6.8*—−27.3% | −4.4*—−19.0% | −13—−65.9% | −4.2*—−20.4% | −8.2*—−41.0% | −12*—−61.0% | −14—−80.8% | −12*—−62.1% | −11*—−54.9% | −12*—−57.7% | −16—−84.4% | −11*—−57.0% | |
| Net income attributable to shareholders | −28—−32.1% | −6.8—−27.3% | −4.4—−19.0% | −13—−65.9% | −4.2*—−20.4% | −8.2—−41.0% | −12—−61.0% | −14—−80.8% | −12*—−62.1% | −11—−54.9% | −12—−57.7% | −16—−84.4% | −11*—−57.0% | |
| Earnings per share, basic | — | -0.12—— | -0.08—— | -0.24—— | — | -0.16—— | -0.23—— | -0.28—— | — | -0.22—— | -0.25—— | -0.33—— | — | |
| Earnings per share, diluted | — | -0.12—— | -0.08—— | -0.24—— | — | -0.16—— | -0.23—— | -0.28—— | — | -0.22—— | -0.25—— | -0.33—— | — | |
| Shares, weighted average (basic) | 55+5.2%— | 55+5.2%— | 55+5.2%— | 54+5.2%— | — | 52+4.0%— | 52+3.8%— | 51+3.6%— | — | 50—— | 50—— | 49—— | — | |
| Shares, weighted average (diluted) | 55+5.2%— | 55+5.2%— | 55+5.2%— | 54+5.2%— | — | 52+4.0%— | 52+3.8%— | 51+3.6%— | — | 50—— | 50—— | 49—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 77—73.8% | 77−16.2%73.8% | 80−21.4%76.0% | 85−21.9%77.4% | 92−23.6%79.8% | 92−22.1%79.5% | 102−14.1%83.2% | 109−14.5%83.9% | 120−12.9%84.3% | 119—82.6% | 118—78.9% | 127—81.8% | 138—82.9% | |
| Receivables | 13—12.7% | 13+37.3%12.7% | 11+18.4%10.9% | 11+12.4%9.7% | 9.7−9.7%8.5% | 9.7−24.6%8.4% | 9.6−51.7%7.9% | 9.4−39.8%7.3% | 11−24.5%7.6% | 13—9.0% | 20—13.3% | 16—10.1% | 14—8.6% | |
| Inventory | 6.5—6.2% | 6.5−18.6%6.2% | 5.7−8.4%5.4% | 7.0+20.7%6.4% | 7.8+22.8%6.7% | 8.0+31.1%6.9% | 6.2−8.4%5.1% | 5.8−15.5%4.5% | 6.3−19.4%4.4% | 6.1—4.2% | 6.8—4.5% | 6.9—4.4% | 7.8—4.7% | |
| Other current assets | 4.2—4.0% | 4.2+19.8%4.0% | 4.6+119%4.4% | 3.9+35.7%3.6% | 3.3+41.2%2.8% | 3.5+21.1%3.0% | 2.1+44.8%1.7% | 2.9+27.0%2.2% | 2.3−11.4%1.6% | 2.9—2.0% | 1.5—1.0% | 2.3—1.5% | 2.6—1.6% | |
| Current assets | 101—96.7% | 101−10.7%96.7% | 101−15.1%96.7% | 107−16.1%97.1% | 113−19.3%97.8% | 114−19.1%97.7% | 119−18.4%97.9% | 127−16.6%97.9% | 140−14.2%97.9% | 140—97.8% | 146—97.7% | 152—97.8% | 163—97.7% | |
| Property, plant and equipment | 1.7—1.6% | 1.7+10.7%1.6% | 1.7+14.2%1.6% | 1.6+9.0%1.5% | 1.6+1.9%1.4% | 1.5+6.7%1.3% | 1.5−1.9%1.2% | 1.5−4.2%1.1% | 1.6−3.7%1.1% | 1.4—1.0% | 1.5—1.0% | 1.6—1.0% | 1.6—1.0% | |
| Right-of-use (leased) assets | 1.1—1.0% | 1.1+89.6%1.0% | 1.2+70.7%1.1% | 1.2+47.1%1.1% | 0.4−53.2%0.4% | 0.6−48.4%0.5% | 0.7−44.8%0.6% | 0.8−37.0%0.6% | 0.9−35.9%0.7% | 1.1—0.8% | 1.3—0.8% | 1.3—0.8% | 1.5—0.9% | |
| Total assets | 105—100% | 105−9.7%100% | 105−14.0%100% | 110−15.4%100% | 115−19.3%100% | 116−19.0%100% | 122−18.5%100% | 130−16.6%100% | 143−14.3%100% | 144—100% | 150—100% | 156—100% | 167—100% | |
| Accounts payable | 2.8—2.7% | 2.8+59.7%2.7% | 1.9−8.6%1.8% | 1.5−46.3%1.4% | 1.3−20.6%1.2% | 1.7+34.3%1.5% | 2.1+8.0%1.7% | 2.8+66.0%2.1% | 1.7−2.3%1.2% | 1.3—0.9% | 1.9—1.3% | 1.7—1.1% | 1.7—1.0% | |
| Debt due within a year | 6.1—5.8% | 6.1—5.8% | 10—9.7% | 3.8—3.5% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0−100%0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 2.2—1.3% | |
| Current liabilities | 20—19.2% | 20+70.2%19.2% | 20+71.7%19.5% | 18+49.8%16.6% | 11−28.7%9.6% | 12−14.3%10.2% | 12−10.2%9.8% | 12+3.7%9.3% | 15+26.2%10.8% | 14—9.6% | 13—8.9% | 12—7.5% | 12—7.4% | |
| Long-term debt | 35—33.3% | 35−12.7%33.3% | 31−23.0%29.2% | 37−7.2%33.5% | 40+2.4%35.0% | 40+17.3%34.5% | 40+17.9%32.6% | 40+17.5%30.5% | 39+24.1%27.6% | 34—23.8% | 34—22.6% | 34—21.7% | 32—19.0% | |
| Lease liabilities (non-current) | 0.7—0.6% | 0.7+1343%0.6% | 0.8+339%0.8% | 0.9+165%0.8% | 0−100%0.0% | 0.0−92.3%0.0% | 0.2−75.5%0.2% | 0.3−59.1%0.3% | 0.5−48.2%0.3% | 0.6—0.4% | 0.7—0.5% | 0.8—0.5% | 0.9—0.5% | |
| Total liabilities | 56—53.2% | 56+7.4%53.2% | 52+0.0%49.6% | 56+7.2%50.9% | 51−7.2%44.5% | 52+6.8%44.7% | 52+8.1%42.6% | 52+12.3%40.1% | 55+19.1%38.7% | 49—33.9% | 48—32.1% | 46—29.8% | 46—27.9% | |
| Retained earnings | −409—−390% | −409—−390% | −402—−383% | −398—−363% | −385—−334% | −381—−327% | −372—−305% | −360—−278% | −346—−242% | −334—−233% | −323—−216% | −311—−200% | −295—−177% | |
| Shareholders' equity | 49—46.8% | 49−23.6%46.8% | 53−24.5%50.4% | 54−30.6%49.1% | 64−26.9%55.5% | 64−32.3%55.3% | 70−31.1%57.4% | 78−28.9%59.9% | 88−27.2%61.3% | 95—66.1% | 102—67.9% | 109—70.2% | 120—72.1% | |
| Total liabilities and equity | 105—100% | 105−9.7%100% | 105−14.0%100% | 110−15.4%100% | 115−19.3%100% | 116−19.0%100% | 122−18.5%100% | 130−16.6%100% | 143−14.3%100% | 144—100% | 150—100% | 156—100% | 167—100% | |
| Shares outstanding | 55—— | 55+5.2%— | 55+5.2%— | 54+5.2%— | 53+5.0%— | 52+4.1%— | 52+3.8%— | 51+3.7%— | 51+3.7%— | 50—— | 50—— | 50—— | 49—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.4−25.2%0.5% | 0.1*+4.8%0.4% | 0.1*−24.8%0.4% | 0.1−30.9%0.5% | 0.1*−38.6%0.5% | 0.1*−33.5%0.5% | 0.1*−32.8%0.6% | 0.1−22.4%0.9% | 0.2*+10.7%0.9% | 0.2*—0.8% | 0.2*—0.9% | 0.2—1.0% | 0.2*—0.8% | |
| Share-based compensation | 11−21.8%12.8% | 2.9+21.2%11.8% | 3.0−22.9%12.7% | 2.9−32.8%14.5% | 2.5*−35.4%12.5% | 2.4−43.8%12.2% | 3.8−11.0%19.6% | 4.2−5.8%24.2% | 3.9*+14.0%20.7% | 4.3—21.4% | 4.3—20.2% | 4.5—23.4% | 3.5*—18.5% | |
| Cash from operating activities | −17—−19.1% | −2.4*—−9.6% | −5.7*—−24.2% | −7.0—−35.7% | −1.8*—−9.0% | −8.7*−2509%−43.8% | −7.5*—−38.6% | −12—−66.3% | −3.5*—−18.1% | 0.4*—1.8% | −9.5*—−44.3% | −9.8—−50.8% | −6.5*—−34.6% | |
| Capital expenditure | — | −0.1*—−0.3% | −0.0*—−0.1% | −0.1—−0.3% | — | −0.2*—−0.9% | −0.2*—−1.1% | 0—0.0% | −0.1*—−0.7% | −0.1*—−0.3% | −0.1*—−0.4% | −0.1—−0.6% | −0.3*—−1.4% | |
| Cash from investing activities | 0.0—0.0% | −0.1*—−0.3% | −0.0*—−0.1% | −0.1—−0.3% | 0.2*—0.8% | −0.2*—−0.9% | −0.2*—−1.1% | 0—0.0% | −0.1*—−0.7% | −0.1*—−0.3% | −0.1*—−0.4% | −0.1—−0.6% | −0.3*—−1.4% | |
| Cash from financing activities | 1.9−67.1%2.2% | 0.1*+376%0.5% | 0.5*−2.3%2.0% | 0.1+450%0.4% | 1.3*−76.5%6.2% | 0.0*−67.1%0.1% | 0.5*+10.0%2.5% | 0.0—0.1% | 5.4*+1333%28.3% | 0.1*—0.4% | 0.4*—2.1% | −0.9—−4.9% | 0.4*—2.0% | |
| Change in cash | −15—−16.9% | −2.4*—−9.4% | −5.2*—−22.3% | −7.0—−35.5% | −0.4*−123%−2.0% | −8.9*−2390%−44.5% | −7.3*—−37.1% | −12—−66.2% | 1.8*—9.4% | 0.4*—1.9% | −9.1*—−42.6% | −11—−56.3% | −6.4*—−34.0% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Sight Sciences, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Interventional Glaucoma$76 M98%-0.2%
- Interventional Dry Eye$2 M2.1%-59%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at Sight Sciences, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Restructuring 1 · Directors and officers 7 · Material agreement 2 · New debt 1 · Unregistered share sale 1 · Shareholder vote 3 · Results announced 12
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officersResults announced | 8-K | |
| Material agreement | 8-K | |
| RestructuringDirectors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| New debtUnregistered share sale | 8-K | |
| Directors and officersResults announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 4, 2026
Acquisitions and funding#
5 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2020 | $23 M | No. 5 | $10 to $50 million | 4 | equity | SEC |
| Mar 2020 | $30 M | No. 4 | $10 to $50 million | — | equity | SEC |
| Aug 2019 | $31 M | No. 3 | $10 to $50 million | 2 | equity | SEC |
| Jul 2017 | $20 M | No. 2 | $10 to $50 million | 25 | equity | SEC |
| Oct 2015 | $7 M | No. 1 | $2 to $10 million | 17 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Sight Sciences, Inc.#
$140 K spent on lobbying the US Congress and federal agencies in 2025, most often on medicare/medicaid.
- Medicare/Medicaid3 reports
Lobbying firms hired in 2025
The McManus Group $140 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $20 K | — | 1 |
| 2025 | $140 K | — | 3 |
| 2024 | $20 K | — | 4 |
| 2023 | $140 K | — | 4 |
| 2022 | $240 K | — | 7 |
| 2021 | $60 K | — | 4 |
| 2020 | $20 K | — | 1 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Sight Sciences” and “Sight Sciences, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Sight Sciences, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $109 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Regulatory Affairs SpecialistRegulatory Affairs Specialists | 1 | $109 K |
Where: Covington, GA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 1 | 1 | $109 K | 1 |
| FY2025 | 1 | 1 | $167 K | 1 |
| FY2024 | 1 | 1 | $107 K | 1 |
| FY2023 | 2 | 2 | $169 K | 2 |
| FY2022 | 1 | 1 | $98 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Sight Sciences, Inc.
FDA drug approvals: Sight Sciences, Inc.#
1 approved applications held.
| Approved | Drug | Kind |
|---|---|---|
| 1996-10-18 | Minoxidil (For Women), Minoxidil (For Men)Minoxidil · ANDA074743 | Generic drug (ANDA) |
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (SIGHT PHARMS), so they follow acquisitions
Product recalls by Sight Sciences, Inc.#
1 recalls since 2015, 921 units in the notices that give a number. Medical devices (FDA): 1.
| Date | What and why | Units | Notice |
|---|---|---|---|
| TearCare version 1.0 SmartHubsOphthalmic devices distributed prior to the recently-obtained 510(k) clearance do not fall within the relevant 510(k) exemption and so their performance characteristics were not evaluated by the FDA prior to distribution.Medical devicesClass II | 921 | Z-1001-2022 |
Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2023 | · | · | · | · | · | · | · | · | · | 25 | · | · | 25 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| 25 people (10% of workforce) | Restructuring planSEC 8-K | “Pursuant to the Plan, the Company intends to (a) reduce its headcount by 25 employees, or approximately 10% of its global workforce, and (b) reduce its operating expenses, principa…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Sight Sciences, Inc. compares in Medical Devices
- Market cap$448 M · higher than 48% of 142
- Revenue$77 M · higher than 36% of 155
- Net margin-32.1% · higher than 31% of 144
- Revenue growth-3.1% · higher than 14% of 104
- Price / sales5.1× · lower than 28% of 96
- Price / book7.0× · lower than 20% of 99
- FCF yield-6.7% · higher than 36% of 76
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Sight Sciences, Inc.🇺🇸 | $448 M | — | -32.1% | -3.1% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- NeuroPace, Inc.$487 M
- Excelsior Medical Co., Ltd.$403 M
- Delcath Systems, Inc.$500 M
- 908 Devices Inc.$503 M
- Taidoc Technology Corporation$383 M
- Orthofix Medical Inc.$377 M
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Sight Sciences, Inc.? Verify and update this profile — free
Show Sight Sciences, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.